All In Biotech

NDA 212887 · Viiv Hlthcare

Vocabria

Cabotegravir Sodium · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Apr 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jan 21, 2021

Approved uses

10

Original approval plus efficacy supplements

Registered trials

97

26 Phase 3, 19 recruiting

FAERS reports

1,605

1,144 serious, 89 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 11, 2025.

HIV-1 Treatment: VOCABRIA is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with EDURANT (rilpivirine) for short-term treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. ( 1.1 ) HIV-1 Pre-Exposure Prophylaxis: VOCABRIA is indicated for short-term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating VOCABRIA for HIV-1 PrEP. ( 1.2 ) VOCABRIA may be used as: • oral lead-in to assess the tolerability of cabotegravir prior to administration of CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) for HIV-1 treatment or APRETUDE (cabotegravir extended-release injectable suspension) for HIV-1 PrEP. ( 1.1 , 1.2 ) • oral therapy for patients who will miss planned injection dosing with CABENUVA for HIV-1 treatment or APRETUDE for HIV-1 PrEP. ( 1.1 , 1.2 ) 1.1 Treatment of HIV-1 Infection VOCABRIA is indicated in combination with EDURANT (rilpivirine) tablets for short-term treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, for use as [see Microbiology ( 12.4 ), Clinical...

Mechanism: Cabotegravir is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 16, 2026 Supplement 12 · Efficacy LetterLabel
  • Sep 20, 2024 Supplement 9 · Efficacy · priority review LetterLabel
  • Sep 20, 2024 Supplement 10 · Efficacy LetterLabel
  • Mar 29, 2022 Supplement 6 · Efficacy · priority review LetterLabel
  • Mar 29, 2022 Supplement 5 · Efficacy · priority review LetterLabel
  • Mar 23, 2022 Supplement 3 · Efficacy LetterLabel
  • Feb 7, 2022 Supplement 2 · Efficacy LetterLabel
  • Jan 31, 2022 Supplement 1 · Efficacy LetterLabel
  • Dec 20, 2021 Supplement 4 · Efficacy · priority review LabelLetter
  • Jan 21, 2021 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
1 products under this application
  • VOCABRIA · CABOTEGRAVIR SODIUM EQ 30MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cabotegravir" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • viral load increased110
  • injection site pain109
  • product dose omission issue89
  • virologic failure66
  • hepatitis b65
  • off label use64
  • pathogen resistance61
  • nausea58
  • fatigue57
  • headache56
  • inappropriate schedule of product administration56
  • hepatitis b reactivation54

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
20172
20193
20202
202182
2022339
2023364
2024313
2025330
2026168

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 117 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.